Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 – $2.0 billion Improves 2025 expected GAAP operating ...
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...
Failure by municipal and national govern­ments in any given country to provide adequately for the needs of both small, medium and large business enterprises can significantly reduce the po­tential of ...
Discover key Q3 2025 earnings insights for Arcturus Therapeutics: pipeline progress, regulatory updates, and financial outlook.
Everyone should learn to vibe code, according to Andrew Ng. "The bar to coding is now lower than it ever has been," Ng said ...